Lusia Sepiashvili
PhD
Dr Lusia Sepiashvili is a Clinical Biochemist at The Hospital for Sick Children where she acts as a scientific resource and provides oversight over various sections of the Clinical Biochemistry Division as part of the Department of Paediatric Laboratory Medicine.
Prior to her current role, she completed a postdoctoral fellowship in Clinical Chemistry at Mayo Clinic, Rochester.
Her research during fellowship was geared towards advancing novel diagnostic techniques and biomarkers into clinical use and improving quality of clinical lab tests.
Furthermore, she has developed research interests in a number of diverse areas in clinical chemistry, including immunology, endocrinology, and autoimmunity.
She also further advanced her expertise in clinical mass spectrometry, building on her experience from doctoral studies at the University of Toronto that focused on translational cancer proteomics.
Research Synopsis
I have diverse academic interests in the field of clinical chemistry.
I am interested in translating new lab tests from research into clinical use and applying novel technologies to advance the clinical utility of lab tests and their throughput.
I enjoy collaborating with clinical colleagues towards laboratory quality improvement and lab test utilization.
Recent Publications
Kaufmann, M., Sepiashvili, L., Singh, R.J. Mass spectrometry assays of vitamin D metabolites. In: Feldman, D., Pike, W., Bouillon, R., Giovannucci, E., Goltzman, D., and Hewison, M., Vitamin D. 4th Edition. Volume 1. San Diego (USA): Academic Press; 2017.
Sepiashvili, L., Dahl, A.R., Meeusen, J.W., Loftus, C.G., Donato, L.J. A Man with Recurrent Ascites after Laparoscopic Cholecystectomy. Clinical Chemistry 2017 Jul;63(7):1199-1202.
Frazer-Abel, A, Sepiashvili, L, Mbughuni, MM, Willrich, MA. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Adv Clin Chem. 2016;77:1-75.
Sepiashvili, L, Bruce, JP, Huang, SH, O'Sullivan, B, Liu, FF, Kislinger, T. Novel insights into head and neck cancer using next-generation "omic" technologies. Cancer Res. 2015 Feb 1;75(3):480-6.
Sepiashvili, L, Waggott, D, Hui, A, Shi, W, Su, S, Ignatchenko, A, Ignatchenko, V, Laureano, M, Huang, SH, Xu, W, Weinreb, I, Waldron, J, O'Sullivan, B, Irish, JC, Boutros, PC, Liu, FF, Kislinger, T. Integrated omic analysis of oropharyngeal carcinomas reveals human papillomavirus (HPV)-dependent regulation of the activator protein 1 (AP-1) pathway. Mol Cell Proteomics. 2014 Dec;13(12):3572-84.
Sepiashvili, L, Hui, A, Ignatchenko, V, Shi, W, Su, S, Xu, W, Huang, SH, O'Sullivan, B, Waldron, J, Irish, JC, Perez-Ordonez, B, Liu, FF, Kislinger, T. Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy. Mol Cell Proteomics. 2012 Nov;11(11):1404-15.